Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of New vs Approved Levothyroxine Formulation
NCT03979274Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Dec 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of levothyroxine sodium in hypothyroidism (2 arms), sponsored by Merck KGaA. Primary endpoints: Maximum Serum Concentration in Pre Dose Corrected Data and Area Under Serum Concentration-Time Curve From Time Zero to The Last Sampling Time in Pre Dose Corrected Data. Started Dec 2019; status: completed.
02
Drugs
levothyroxine sodium
03
Conditions
hypothyroidism
Beyond the preview
Go deeper on NCT03979274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03979274.